AMGEN INC (AMGN) AI Stock Summary

Snapshot

Amgen is a cash-generating biotech giant. FY 2025 revenue hit $36.74B (up 9.9% year-over-year), with $7.71B in net profit and a healthy 29% operating margin. The business produces plenty of cash, generating $8.10B in free cash flow last year. It holds $9.13B in cash against $54.60B in debt. The stock currently sits in the upper portion of its 52-week range.

What's Happening Right Now

• Tue 21st Jul '26 · Legal Settlement: Amgen agreed to pay $74 million to settle a lawsuit alleging it delayed disclosing a potential $10.7 billion tax bill.
• Tue 19th May '26 · Management Change: Peter Griffith retired as Executive Vice President and CFO, with Thomas Dittrich returning to take over the role.
• Mon 4th May '26 · Investment: Amgen announced an additional $300 million investment in its U.S. manufacturing network, totaling nearly $2 billion over the last year.
• Thu 30th Apr '26 · Earnings: The company reported Q1 2026 revenue of $8.62B and raised its full-year revenue guidance to between $37.1B and $38.5B.

Bottom Line

Amgen is a financially healthy machine with growing sales and strong margins. The core business is performing well, with 16 drugs delivering double-digit growth. However, the stock trades near its 52-week high and above the median analyst price target, suggesting the market is pricing it for continued success rather than offering a discount. Investors looking for a bargain might find the valuation rich.